1 / 15

Session 4 Adverse Event Reporting

Session 4 Adverse Event Reporting. Deborah A. Zarin, M.D. Pilot Quality Control Project Recommendation to Secretary – Narrative Summaries. Expanded Clinical Trial Registry. REGISTRY. New Administration Transition Phase. Public Meeting. 9/27/07. 12/26/07. 9/27/08. 3/27/09. 9/27/10.

haig
Download Presentation

Session 4 Adverse Event Reporting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Session 4Adverse Event Reporting Deborah A. Zarin, M.D.

  2. Pilot Quality Control Project • Recommendation to Secretary – Narrative Summaries Expanded Clinical Trial Registry REGISTRY New Administration Transition Phase Public Meeting 9/27/07 12/26/07 9/27/08 3/27/09 9/27/10 90 d 1 yr 18 m 2 yr 3 yr Enactment Expansion by Rulemaking: Final Rule Additional Adverse Events Data RESULTS Launch Basic Results Database Linking to existing results information at FDA and NIH

  3. Adverse Events - Default • If the Secretary fails to issue regulation by 24 months after the date of enactment [September 2009] • SERIOUS ADVERSE EVENTS • Table of anticipated and unanticipated serious adverse events • Grouped by organ system • Number and frequency of event in each arm of clinical trial • FREQUENT ADVERSE EVENTS • Table of anticipated and unanticipated adverse events • Exceed a frequency of 5 percent within any arm of clinical trial • Grouped by organ system • Number and frequency of event in each arm of clinical trial

  4. Published Adverse Events

  5. Results RecordAdverse Events Adverse Events Esomeprazole N=1,205* Omeprazole N=1,200 Serious Adverse Events N/A N/A Frequent Adverse Events (>5%) Nervous System Disorders Headache 75 (6.2%) 70 (58%) Gastrointestinal Disorders Diarrhea 67 (5.6%) 66 (5.5%) Nausea 61 (5.1%) 57 (4.8%) * Of the 2,425 patients with erosive esophagitis randomized to study medication, 2,405 patients received at least one dose of either esomeprazole (n = 1,205) or omeprazole (n = 1,200)

  6. Issues in Reporting Adverse Event Data • Definitions: AE, serious AE • Characteristics to consider • Frequency (threshold) • Attributable? • Statistically significant? • # assessed (and time frame) • Systematically assessed? • How to count and how to report • Splitting vs. lumping • Recurrent events in same patient

  7. Frequency • US Public Law 110-85 Default: Frequent AEs • AEs that exceed a frequency of 5% • CONSORT • Poor reporting practice: “Reporting only the adverse events observed at a certain frequency or rate threshold (for example, >3% or >10%).” • FDA – Adverse Reactions Section of Labeling – General Principles for Presenting Adverse Events in a Table • The frequency cutoff for the listing of common adverse reactions identified from clinical trials (usually the adverse reactions table) must be appropriate to the safety database • Factors that could influence selection of a frequency cut-off include the size of the safety database, the designs of the trials in the database, and the nature of the indication.  The frequency cutoff should be noted in the listing or table header, in the text accompanying the listing or table, or in a footnote. Ann Intern Med. 2004;141:781-788 FDA Guidance for Industry - Adverse Reactions Section of Labeling for Human - Prescription Drug and Biological Products — Content and Format

  8. Key Implementation Issues • Default v. regulation • Default as voluntary “pilot” to inform rulemaking? • Timing of submissions—relationship to completion date and outcome measures

  9. Example • A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 [lapatinib] and Capecitabine (Xeloda) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer • GlaxoSmithKline • Sources: • GSK clinical trial register • New England Journal of Medicine • Drugs @ FDA: Lapatinib label

  10. GSK Clinical Trial Register Timing: AEs collected from first dose … to 30 days after last dose Most Frequent Adverse Events on Therapy Frequency: Most frequent 10 events in each group Attribution: Not specified http://ctr.gsk.co.uk/Summary/lapatinib/studylist.asp

  11. GSK Clinical Trial Register Any Serious Adverse Events on Therapy Timing: On-Therapy (first dose of study medication to last day of study medication) Frequency: Any (i.e., all) Attribution: related – considered by the investigator to be related to study medication

  12. New England Journal of Medicine Timing: Adverse events through November 15, 2005 Frequency: Not specified Attribution: Not specified N Engl J Med 2006;355:2733-43

  13. FDA Approved Label Timing: Not specified Frequency: Occurring in > 10% of patients Attribution: Not specified

More Related